Press Releases

 
Press Releases
  Date Title View
Apr 13, 2011
NEW HAVEN, Conn., April 13, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department ...
Apr 7, 2011
NEW HAVEN, Conn., April 7, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Numbe...
Apr 10, 2009
BRANFORD, Conn., April 10 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a developer of drugs to treat serious neurological and psychiatric disorders, today announced the close of a $20 million Series B financing. The funding comes on the heels of the Company's recent announcement of positive Phase...
Mar 3, 2009
BRANFORD, Conn., March 3 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. today announced that it met its primary endpoint for its Phase 2 clinical trial investigating the safety and efficacy of ganaxolone as adjunctive therapy in adults with partial onset seizures, a type of epilepsy. In this trial, ganaxolone dem...
Oct 7, 2008
RANFORD, Conn., Oct. 7 /PRNewswire/ -- Marinus Pharmaceuticals, a developer of specialty therapeutics to treat neurological and psychiatric disorders, today announced that it has completed its Phase 2 clinical trial of ganaxolone for the treatment of infantile spasms (also called West syndrome) and that the final patient has completed enrollment...
May 4, 2007
BRANFORD, Conn., May 4 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on novel drugs to treat serious neurological disorders, today announced that it is enrolling patients in an international, multi-center, placebo controlled Phase IIb study of its lead compound, Ganaxolone, as an adjunctive treatm...
Feb 28, 2007
BRANFORD, Conn., Feb. 28 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on novel drugs to treat serious neurological disorders, today announced the dosing of the first patient in an international, multi-center, randomized Phase IIb study of its lead compound, ganaxolone, in infants suffering from Infant...
Oct 25, 2005
BRANFORD, Conn., Oct. 25 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a new developer of drugs to treat serious central nervous system disorders, today announced the closing of a $29.4 million Series A financing round. The financing was led by Domain Associates, Sofinnova Ventures and Canaan Partners, with participation by Foundation Medical P...
FirstPrevious
...
7
= add release to Briefcase